TY - JOUR
T1 - Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer
AU - Grivas, Petros D.
AU - Robins, Diane M.
AU - Hussain, Maha
N1 - Funding Information:
Grants: NIH-RO1-CA144032; DOD W81XWH-08-1-0034. Petros D. Grivas obtained his M.D. and subsequently his Ph.D. from the University of Patras School of Medicine, Greece. He completed his Internal Medicine residency at Hahnemann University Hospital/Drexel University College of Medicine in Philadelphia, US. He is currently a second year fellow in the Hematology/Oncology Program, at the University of Michigan. Dr. Grivas is a member of the American Association of Clinical Oncology (ASCO) and the American Association of Cancer Research (AACR). He is member of the Editorial Board and serves as a manuscript reviewer at several international scientific journals. Dr. Grivas is the author of over 20 peer-reviewed articles, and a book chapter in Oncology. He has given several presentations in scientific conferences, and has received several Awards and Scholarships, including an Award from European School of Oncology (ESO), and the ASCO Conquer Foundation Merit Award. His research interests include experimental and novel therapeutics in urothelial and prostate cancers, in the basic, translational and clinical trial settings. Diane M. Robins obtained her B.S. from Yale University and her Ph.D. from Stanford University, both in Biological Sciences. Following postdoctoral studies at the Columbia University Cancer Center, she became an Assistant Professor in Columbia's Department of Biological Sciences. She subsequently joined the Department of Human Genetics at the University of Michigan, where she is currently a Professor as well as a Research Scientist in Reproductive Sciences, and the Director of Graduate Studies in Human Genetics. Dr. Robins is on several Editorial Boards, including Molecular Endocrinology and Steroids. She has been a member and Chair of numerous study sections, including those for the American Cancer Society, the NIH and the Department of Defense, and served on the ACS Council and the Board of Scientific Counselors of the National Toxicology Program. She is active in the Endocrine Society, including being the Basic Science Chair for Endo 2010 and the overall Chair for Endo 2013. She has authored more than 75 publications and several book chapters, and has given numerous named lectures and plenary addresses. Her primary research interests lie in hormonal regulation of gene expression, particularly androgen receptor action and its role in prostate cancer. Maha Hussain is a graduate of the Baghdad University Medical School and completed her internal medicine residency and medical oncology fellowship at Wayne State University. Dr. Hussain is a Professor of Medicine and Urology and the Associate Director for Clinical Research at the University of Michigan Comprehensive Cancer Center (UMCC) and a Co-leader of its Prostate Cancer Program. She is the Associate Chief for Clinical Research at the Division of Hematology/Oncology, Department of Internal Medicine. Dr. Hussain is an internationally recognized clinical researcher and expert in genitourinary malignancies particularly bladder and prostate cancers. Her research is focused on novel therapeutic interventions and designs. The author of over 165 scholarly articles and book chapters, Dr. Hussain has served on the editorial boards for several national and international specialty publications. Nationally, Dr. Hussain serves as the co-chair for the Prostate Cancer sub-committee of SWOG GU committee. She is a member of several federal and national scientific review panels including NCI, DOD, and AUA. Dr. Hussain is the 2012 chair elect of the Integration Panel of US Army Medical Research and Materiel Command (USAMRMC) Prostate Cancer Research Program. She has served as chair of the Education Committee of ASCO and was the Chair for 2011 ASCO Genitourinary Cancer Symposium Program Committee. She has served as a member and the Chair for the FDA Oncology Drug Advisory Committee (ODAC).
PY - 2013/1
Y1 - 2013/1
N2 - Androgen deprivation is the cornerstone of the management of metastatic prostate cancer. Despite several decades of clinical experience with this therapy there are no standard predictive biomarkers for response. Although several candidate genetic, hormonal, inflammatory, biochemical, metabolic biomarkers have been suggested as potential predictors of response and outcome, none has been prospectively validated nor has proven clinical utility to date. There is significant heterogeneity in the depth and duration of hormonal response and in the natural history of advanced disease; therefore to better optimize/individualize therapy and for future development, identification of biomarkers is critical. This review summarizes the current data on the role of several candidate biomarkers that have been evaluated in the advanced/metastatic disease setting.
AB - Androgen deprivation is the cornerstone of the management of metastatic prostate cancer. Despite several decades of clinical experience with this therapy there are no standard predictive biomarkers for response. Although several candidate genetic, hormonal, inflammatory, biochemical, metabolic biomarkers have been suggested as potential predictors of response and outcome, none has been prospectively validated nor has proven clinical utility to date. There is significant heterogeneity in the depth and duration of hormonal response and in the natural history of advanced disease; therefore to better optimize/individualize therapy and for future development, identification of biomarkers is critical. This review summarizes the current data on the role of several candidate biomarkers that have been evaluated in the advanced/metastatic disease setting.
KW - Androgen deprivation therapy (ADT)
KW - Androgen receptor (AR)
KW - Androgens
KW - Hormonal therapy
KW - Predictive biomarkers
KW - Prognostic biomarkers
KW - Prostate cancer
KW - Prostate-specific antigen (PSA)
UR - http://www.scopus.com/inward/record.url?scp=84870778852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870778852&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2012.05.003
DO - 10.1016/j.critrevonc.2012.05.003
M3 - Review article
C2 - 22705096
AN - SCOPUS:84870778852
SN - 1040-8428
VL - 85
SP - 82
EP - 93
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 1
ER -
